ALKS

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.84
Percentage change -2.83	%

Peers: AMGN LLY MRK JNJ PFE BIIB BMY VRTX GILD REGN

| Held by: IJR VTI VB IWM VXF VBK AVUV XBI SPSM FBT

Scroll to Statements

Index	RUT	P/E	13.74	EPS (ttm)	2.10	Insider Own	2.26%	Shs Outstand	164.85M	Perf Week	-1.80%
Market Cap	4.76B	Forward P/E	16.97	EPS next Y	1.70	Insider Trans	-11.07%	Shs Float	161.17M	Perf Month	-6.27%
Enterprise Value	3.95B	PEG	-	EPS next Q	0.36	Inst Own	104.09%	Short Float	7.36%	Perf Quarter	6.85%
Income	352.71M	P/S	3.14	EPS this Y	-43.51%	Inst Trans	2.76%	Short Ratio	6.87	Perf Half Y	2.74%
Sales	1.51B	P/B	3.15	EPS next Y	4.16%	ROA	16.91%	Short Interest	11.86M	Perf YTD	0.31%
Book/sh	9.17	P/C	5.38	EPS next 5Y	-20.59%	ROE	25.71%	52W High	36.45 -20.85%	Perf Year	23.77%
Cash/sh	5.36	P/FCF	9.88	EPS past 3/5Y	- -	ROIC	22.33%	52W Low	23.12 24.78%	Perf 3Y	-2.56%
Dividend Est.	-	EV/EBITDA	9.42	Sales past 3/5Y	9.89% 5.87%	Gross Margin	84.04%	Volatility	3.09% 2.70%	Perf 5Y	54.48%
Dividend TTM	-	EV/Sales	2.61	EPS Y/Y TTM	-17.53%	Oper. Margin	25.84%	ATR (14)	0.83	Perf 10Y	-50.79%
Dividend Ex-Date	-	Quick Ratio	2.92	Sales Y/Y TTM	-12.31%	Profit Margin	23.30%	RSI (14)	41.59	Recom	1.65
Dividend Gr. 3/5Y	- -	Current Ratio	3.33	EPS Q/Q	-37.48%	SMA20	-1.55%	Beta	0.48	Target Price	41.19
Payout	0.00%	Debt/Eq	0.05	Sales Q/Q	-12.52%	SMA50	-4.50%	Rel Volume	0.81	Prev Close	29.69
Employees	1800	LT Debt/Eq	0.04	Earnings	Jul 29 BMO	SMA200	-4.56%	Avg Volume	1.73M	Price	28.85
IPO	Jul 16, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.20% 1.19%	Trades		Volume	1,404,342	Change	-2.83%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Goldman	Buy	$43
Jun-17-25	Upgrade	UBS	Neutral → Buy	$42
May-28-25	Initiated	Needham	Buy	$45
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$40
Mar-04-25	Upgrade	UBS	Sell → Neutral	$21 → $38
Feb-11-25	Initiated	Deutsche Bank	Buy	$40
Nov-05-24	Upgrade	Stifel	Hold → Buy	$25 → $36
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35
Apr-20-22	Initiated	Goldman	Buy	$35
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight	$32
Dec-01-21	Initiated	Citigroup	Neutral	$22

Show Previous Ratings

Today 04:00PM	Alkermes to Report Second Quarter Financial Results on July 29, 2025 (PR Newswire)
09:47AM	DoorDash, Southwest downgraded: Wall Street's top analyst calls (The Fly)
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
09:55AM	How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% (Zacks)
Jul-11-25 12:12PM	FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill (Zacks)
12:10PM	Loading…
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
Jul-09-25 06:15AM	Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck (GlobeNewswire)
Jul-03-25 08:42AM	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore (Zacks)
Jul-02-25 09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 11:40AM	ALKS or CSLLY: Which Is the Better Value Stock Right Now? (Zacks)
Jun-18-25 09:51AM	Roku upgraded, Sarepta downgraded: Wall Streets top analyst calls (TipRanks)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-05-25 11:30AM	Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? (Zacks)
Jun-02-25 04:00PM	Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (PR Newswire)
07:00AM	Loading…
07:00AM	Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences (PR Newswire)
May-29-25 07:00AM	Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 (PR Newswire)
May-19-25 08:00AM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
May-03-25 05:42PM	Alkermes plc (ALKS): Among Billionaire Jim Simons' RenTech's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-02-25 11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
03:01AM	Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... (GuruFocus.com)
May-01-25 04:31PM	Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible (Seeking Alpha) +6.29%
11:21AM	Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
11:00AM	Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings (Zacks)
08:25AM	Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates (Zacks)
07:27AM	Alkermes: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports First Quarter 2025 Financial Results (PR Newswire)
Apr-30-25 10:58AM	Do Options Traders Know Something About Alkermes Stock We Don't? (Zacks)
07:00AM	New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) (PR Newswire)
Apr-29-25 10:01AM	Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
10:02AM	Loading…
Apr-24-25 10:02AM	Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 04:00PM	Alkermes to Report First Quarter Financial Results on May 1, 2025 (PR Newswire)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
Apr-02-25 04:00PM	Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
10:18AM	Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia (Clinical Trials Arena)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 07:00AM	Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia (PR Newswire)
Mar-27-25 07:00AM	New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder (PR Newswire)
Mar-25-25 12:44PM	Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? (Zacks)
Mar-22-25 08:00AM	GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait (Investor's Business Daily)
Mar-17-25 11:21AM	Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points (Investor's Business Daily)
07:53AM	Five Irish Stocks Near Buy Points To Add Green To Your Portfolio On St. Patrick's Day (Investor's Business Daily)
Mar-14-25 11:30AM	Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? (Zacks)
10:54AM	Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-01-25 03:25PM	Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-26-25 04:00PM	Alkermes to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-13-25 02:06AM	Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone (GuruFocus.com) +7.46%
Feb-12-25 09:30AM	Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:40AM	Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:54AM	Alkermes: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 (PR Newswire)
Feb-11-25 07:23AM	Earnings To Watch: Alkermes PLC (ALKS) Reports Q4 2024 Result (GuruFocus.com)
Feb-10-25 09:16AM	What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings (Zacks)
03:00AM	Are orexins the next golden child of neuroscience? (Pharma Voice)
Feb-05-25 04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 (PR Newswire)
Jan-13-25 12:48PM	Oneras validation trial of home polysomnography sleep device succeeds (Clinical Trials Arena)
Jan-02-25 04:00PM	Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-26-24 12:38PM	Axsome Therapeutics eyes approval after Phase III narcolepsy win (Clinical Trials Arena)
Nov-25-24 04:00PM	Alkermes to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-21-24 08:46AM	Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock? (Zacks)
Nov-11-24 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
Nov-07-24 07:00AM	Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences (PR Newswire)
Oct-25-24 03:07AM	Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ... (GuruFocus.com)
Oct-24-24 11:00AM	Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates (Zacks)
07:10AM	Alkermes: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-23-24 09:05AM	Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-22-24 09:15AM	Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Oct-17-24 04:00PM	Alkermes to Report Third Quarter Financial Results on October 24, 2024 (PR Newswire)
Oct-14-24 04:13PM	Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits (Investor's Business Daily)
Oct-12-24 01:04PM	Is Alkermes (ALKS) The Most Undervalued Quality Stock To Buy According To Analysts? (Insider Monkey)
Oct-11-24 09:50AM	Here's Why Alkermes (ALKS) is a Strong Momentum Stock (Zacks) +5.63%
Oct-10-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Sep-25-24 08:00AM	Alkermes to Host Investor Event to Review Orexin Portfolio Strategy (PR Newswire)
Sep-23-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
07:00AM	Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 (PR Newswire)
Sep-20-24 09:40AM	Here's Why Alkermes (ALKS) is a Strong Value Stock (Zacks)
Sep-19-24 04:00PM	Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference (PR Newswire)
Sep-13-24 07:00AM	Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards Program (PR Newswire)
Sep-05-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Sep-04-24 09:40AM	Why Alkermes (ALKS) is a Top Value Stock for the Long-Term (Zacks)
Aug-28-24 04:00PM	Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-23-24 11:30AM	Alkermes (ALKS) Down 0.2% Since Last Earnings Report: Can It Rebound? (Zacks)
11:12AM	Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680 (Zacks)
04:52AM	Alkermes launches Phase II trial of ALKS 2680 for narcolepsy type 2 (Clinical Trials Arena)
Aug-22-24 07:00AM	Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 (PR Newswire)
Aug-20-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Aug-19-24 09:40AM	Here's Why Alkermes (ALKS) is a Strong Value Stock (Zacks)
Aug-16-24 09:50AM	Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-01-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Jul-30-24 09:40AM	Why Alkermes (ALKS) is a Top Value Stock for the Long-Term (Zacks)
Jul-25-24 10:44AM	Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat (Zacks) +5.77%
Jul-24-24 09:30AM	Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +6.04%
08:15AM	Alkermes (ALKS) Lags Q2 Earnings Estimates (Zacks)
07:21AM	Alkermes: Q2 Earnings Snapshot (Associated Press Finance)
07:18AM	Alkermes Reiterates FY24 Revenue Outlook - Update (RTT News)
07:00AM	Alkermes plc Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-17-24 04:00PM	Alkermes to Report Second Quarter Financial Results on July 24, 2024 (PR Newswire)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 09 '25	Sale	31.95	3,333	106,489	89,542	Jun 10 04:39 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 10 '25	Sale	31.09	3,334	103,654	86,208	Jun 10 04:39 PM
Nichols Christian Todd	Officer	Jun 10 '25	Proposed Sale	31.09	3,334	103,654		Jun 10 04:29 PM
Nichols Christian Todd	Officer	Jun 09 '25	Proposed Sale	31.95	3,333	106,489		Jun 09 04:08 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 28 '25	Sale	34.00	1,938	65,892	7,717	Feb 28 05:19 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 25 '25	Sale	35.26	3,743	131,978	7,717	Feb 25 06:38 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 20 '25	Sale	35.69	1,327	47,361	7,717	Feb 20 05:18 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 13 '25	Option Exercise	30.12	144,419	4,350,097	202,294	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 12 '25	Option Exercise	19.64	199,196	3,912,871	262,796	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 12 '25	Sale	32.78	204,921	6,718,278	57,875	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 13 '25	Sale	35.53	144,419	5,130,698	57,875	Feb 14 05:12 PM
Hopkinson Craig C.	Officer	Feb 13 '25	Proposed Sale	35.53	144,419	5,130,694		Feb 13 04:36 PM
Hopkinson Craig C.	Officer	Feb 12 '25	Proposed Sale	32.78	204,921	6,718,276		Feb 12 04:19 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 30 '25	Option Exercise	22.22	97,632	2,169,137	145,208	Jan 31 08:42 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 30 '25	Sale	32.05	100,918	3,234,382	44,290	Jan 31 08:42 PM
Hopkinson Craig C.	Officer	Jan 30 '25	Proposed Sale	32.05	100,918	3,234,380		Jan 30 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 09 '24	Option Exercise	22.70	48,997	1,112,259	108,727	Dec 09 08:53 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 09 '24	Sale	32.07	61,151	1,961,406	47,576	Dec 09 08:53 PM
LAURENCIN CATO T	Director	Dec 09 '24	Option Exercise	22.52	2,691	60,601	25,704	Dec 09 08:51 PM
LAURENCIN CATO T	Director	Dec 09 '24	Sale	31.85	2,691	85,708	23,013	Dec 09 08:51 PM
LAURENCIN CATO T	Director	Dec 09 '24	Proposed Sale	31.85	2,691	85,708		Dec 09 05:27 PM
Hopkinson Craig C.	Officer	Dec 09 '24	Proposed Sale	32.07	61,151	1,961,404		Dec 09 05:24 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 05 '24	Sale	31.50	9,221	290,462	59,730	Dec 05 06:01 PM
Hopkinson Craig C.	Officer	Dec 05 '24	Proposed Sale	31.50	9,221	290,462		Dec 05 04:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 04 '24	Sale	30.77	14,349	441,550	68,951	Dec 04 04:52 PM
Hopkinson Craig C.	Officer	Dec 04 '24	Proposed Sale	30.77	14,349	441,550		Dec 04 04:19 PM
Nichols Christian Todd	Officer	Nov 27 '24	Proposed Sale	29.15	5,208	151,813		Nov 27 04:33 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Nov 27 '24	Sale	29.15	5,208	151,813	60,703	Nov 27 04:22 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 11 '24	Option Exercise	20.03	43,058	862,452	142,296	Nov 12 04:48 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 11 '24	Sale	30.08	58,996	1,774,576	83,300	Nov 12 04:48 PM
Hopkinson Craig C.	Officer	Nov 11 '24	Proposed Sale	30.08	58,996	1,774,578		Nov 12 04:15 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 06 '24	Sale	29.53	10,471	309,169	99,238	Nov 06 07:47 PM
Hopkinson Craig C.	Officer	Nov 06 '24	Proposed Sale	29.53	10,471	309,169		Nov 06 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Alkermes plc

Upgrade your FINVIZ experience